콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

모든 문서 보기

46412

Supelco

Medroxyprogesterone 17-acetate

VETRANAL®, analytical standard

동의어(들):

17α-Acetoxy-6α-methylprogesterone, 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-acetate, 6α-Methyl-17α-acetoxyprogesterone, 6α-Methyl-17α-hydroxyprogesterone acetate

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C24H34O4
CAS Number:
71-58-9
Molecular Weight:
386.52
Beilstein:
2066112
EC Number:
200-757-9
MDL number:
MFCD00010483
UNSPSC 코드:
41116107
PubChem Substance ID:
329757168
NACRES:
NA.24

Grade

analytical standard

Quality Level

100

제품 라인

VETRANAL®

유통기한

limited shelf life, expiry date on the label

기술

HPLC: suitable
gas chromatography (GC): suitable

mp

206-207 °C (lit.)

응용 분야

pharmaceutical (small molecule)

형식

neat

SMILES string

[H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4(OC(C)=O)C(C)=O

InChI

1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1

InChI key

PSGAAPLEWMOORI-PEINSRQWSA-N

유전자 정보

human ... PGR(5241)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

애플리케이션

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

법적 정보

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

픽토그램

Health hazard
GHS08

신호어

Warning

유해 및 위험 성명서

H351,H413

Hazard Classifications

Aquatic Chronic 4 - Carc. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

개인 보호 장비

dust mask type N95 (US), Eyeshields, Gloves

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number
BCCF4063
BCCC4029
BCBS8482V

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

COA 검색

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

이미 열람한 고객

Slide 1 of 1

1 of 1

Tamoxifen ≥99%

Sigma-Aldrich

T5648

Tamoxifen

Léanie Kleynhans et al.
Infection and immunity, 81(4), 1234-1244 (2013-02-06)
The contraceptive depot medroxyprogesterone acetate (DMPA), with progestin as the single active compound, possesses selective glucocorticoid activity and can alter the expression of glucocorticoid receptor-regulated genes. We therefore propose that pharmacological doses of DMPA used for endocrine therapy could have
Lee L Lanza et al.
Obstetrics and gynecology, 121(3), 593-600 (2013-05-03)
Depot medroxyprogesterone acetate (DMPA) reversibly reduces bone mineral density. To estimate the extent to which DMPA might increase fracture risk, we undertook a retrospective cohort study of fractures in DMPA users and users of non-DMPA contraceptives, using the General Practice
Robert A Wild et al.
Menopause (New York, N.Y.), 20(3), 254-260 (2013-02-26)
Our objective was to determine whether metabolic syndrome (MetS) or its components modified the effect of hormone therapy (HT) on the risk of coronary heart disease (CHD) events in the Women's Health Initiative clinical trials. We performed a nested case-control
Richard P H Huijbregts et al.
Endocrinology, 154(3), 1282-1295 (2013-01-29)
Recent observational studies indicate an association between the use of hormonal contraceptives and acquisition and transmission of HIV-1. The biological and immunological mechanisms underlying the observed association are unknown. Depot medroxyprogesterone acetate (DMPA) is a progestin-only injectable contraceptive that is
JoAnn E Manson et al.
JAMA, 310(13), 1353-1368 (2013-10-03)
Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.